Levofloxacin 0.5.% Nipro Uses

sponsored
Did you have any side effects with this medicine?

What is Levofloxacin 0.5.% Nipro?

Levofloxacin 0.5.% Nipro is in a group of antibiotics called fluoroquinolones (flor-o-KWIN-o-lones). Levofloxacin 0.5.% Nipro fights bacteria in the body.

Levofloxacin 0.5.% Nipro is used to treat bacterial infections of the skin, sinuses, kidneys, bladder, or prostate. Levofloxacin 0.5.% Nipro is also used to treat bacterial infections that cause bronchitis or pneumonia, and to treat people who have been exposed to anthrax or plague.

Levofloxacin 0.5.% Nipro may also be used for purposes not listed in this medication guide.

Levofloxacin 0.5.% Nipro indications

infoAn indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Levofloxacin 0.5.% Nipro and other antibacterial drugs, Levofloxacin 0.5.% Nipro should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Levofloxacin 0.5.% Nipro injection is indicated for the treatment of adults (≥ 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Levofloxacin 0.5.% Nipro injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form).

Culture and susceptibility testing

Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to Levofloxacin 0.5.% Nipro. Therapy with Levofloxacin 0.5.% Nipro may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected.

As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with Levofloxacin 0.5.% Nipro. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance.

1.1 Nosocomial Pneumonia

Levofloxacin 0.5.% Nipro is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended.

1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen

Levofloxacin 0.5.% Nipro is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae.

MDRSP isolates are isolates resistant to two or more of the following antibacterials: penicillin (MIC ≥ 2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.

1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen

Levofloxacin 0.5.% Nipro is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae.

1.4 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens

Levofloxacin 0.5.% Nipro is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis.

1.5 Acute Bacterial Exacerbation of Chronic Bronchitis

Levofloxacin 0.5.% Nipro is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin‑susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.

1.6 Complicated Skin and Skin Structure Infections

Levofloxacin 0.5.% Nipro is indicated for the treatment of complicated skin and skin structure infections due to methicillin‑susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis.

1.7 Uncomplicated Skin and Skin Structure Infections

Levofloxacin 0.5.% Nipro is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes.

1.8 Chronic Bacterial Prostatitis

Levofloxacin 0.5.% Nipro is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis.

1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen

Levofloxacin 0.5.% Nipro is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis.

1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen

Levofloxacin 0.5.% Nipro is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa.

1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen

Levofloxacin 0.5.% Nipro is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia.

1.12 Uncomplicated Urinary Tract Infections

Levofloxacin 0.5.% Nipro is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus.

1.13 Inhalational Anthrax (Post-Exposure)

Levofloxacin 0.5.% Nipro is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of Levofloxacin 0.5.% Nipro is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin 0.5.% Nipro has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of Levofloxacin 0.5.% Nipro in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged Levofloxacin 0.5.% Nipro therapy should only be used when the benefit outweighs the risk.

1.14 Plague

Levofloxacin 0.5.% Nipro is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of Levofloxacin 0.5.% Nipro could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals.

How should I use Levofloxacin 0.5.% Nipro?

Use Levofloxacin 0.5.% Nipro as directed by your doctor. Check the label on the medicine for exact dosing instructions.

  • Levofloxacin 0.5.% Nipro is only for the eye. Do not get it in your nose or mouth.
  • To use Levofloxacin 0.5.% Nipro in the eye, first, wash your hands. Tilt your head back. Using your index finger, pull the lower eyelid away from the eye to form a pouch. Drop the medicine into the pouch and gently close your eyes. Immediately use your finger to apply pressure to the inside corner of the eye for 1 to 2 minutes. Do not blink. Remove excess medicine around your eye with a clean, dry tissue, being careful not to touch your eye. Wash your hands to remove any medicine that may be on them.
  • To prevent germs from contaminating your medicine, do not touch the applicator tip to any surface, including the eye. Keep the container tightly closed.
  • Do not wear contact lenses while you are using Levofloxacin 0.5.% Nipro. Take care of your contact lenses as directed by the manufacturer. Check with your doctor before you use them.
  • Levofloxacin 0.5.% Nipro works best if it is used at the same time each day.
  • To clear up your infection completely, use Levofloxacin 0.5.% Nipro for the full course of treatment. Keep using it even if you feel better in a few days.
  • Do not miss any doses of Levofloxacin 0.5.% Nipro. If you miss a dose of Levofloxacin 0.5.% Nipro, use it as soon as you remember. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Levofloxacin 0.5.% Nipro.

Uses of Levofloxacin 0.5.% Nipro in details

infoThere are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored

Levofloxacin 0.5.% Nipro is used to treat bacterial infections of the respiratory tract, urinary tract, ear, tooth and prostate gland. It is also used to treat skin and soft tissue infections, anthrax and plague.

Levofloxacin 0.5.% Nipro description

infoPharmacology is a crucial part of medicine wherein various medications are used to advance the well-being of an individual. Some drugs cure the infection or a disease; few prevent the occurrence of a symptom or a disease, and few are used in long-term treatment of the disease. Drugs are obtained from the plants as well as they can be synthesized organically. The drugs are used in various combinations or a single drug by the pharmaceutical industry during its preparation. The half-life of each medicine is different, and the dosage of the drug depends on the half-life of the drug.

Each tablet contains Levofloxacin 0.5.% Nipro 250 mg as active ingredient corresponding to Levofloxacin 0.5.% Nipro hemihydrate 256.23 mg.

Cravit IV also contains the following inactive ingredients: Sodium chloride; sodium hydroxide; hydrochloric acid (qs: pH 4.8) and water for injection for a volume of 100 mL (Na+ concentration: 154 mmol/L).

Levofloxacin 0.5.% Nipro is a synthetic broad-spectrum antibacterial agent for oral and IV administration. Chemically, Levofloxacin 0.5.% Nipro, a chiral fluorinated carboxyquinolone, is the pure (-)-(S)-enantiomer of the racemic drug substance ofloxacin. Levofloxacin 0.5.% Nipro is (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4 benzoxazine-6-carboxylic acid hemihydrate.

Its empirical formula is C18H20FN3O4·½H2O and its molecular weight is 370.38.

Levofloxacin 0.5.% Nipro is a light yellowish-white to yellow-white crystal or crystalline powder. The molecule exists as a zwitterion at the pH conditions in the small intestine. The data demonstrate that from pH 0.6-5.8, the solubility of Levofloxacin 0.5.% Nipro is essentially constant (approximately 100 mg/mL). Levofloxacin 0.5.% Nipro is considered soluble to freely soluble in this pH range, as defined by USP nomenclature. Above pH 5.8, the solubility increases rapidly to its maximum at pH 6.7 (272 mg/mL) and is considered freely soluble in this range. Above pH 6.7, the solubility decreases and reaches a minimum value (about 50 mg/mL) at a pH of approximately 6.9. Levofloxacin 0.5.% Nipro has the potential to form stable coordination compounds with many metal ions. This in vitro chelation potential has the following formation order: A1+3 > Cu+2 > Zn+2 > Mg+2 > Ca+2.


sponsored

Active ingredient matches for Levofloxacin 0.5.% Nipro:

Levofloxacin in Japan.


List of Levofloxacin 0.5.% Nipro substitutes (brand and generic names)

Sort by popularity
Unit description / dosage (Manufacturer)Price, USD

References

  1. DailyMed. "LEVOFLOXACIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailymed/se... (accessed September 18, 2017).
  2. Wikipedia. "levofloxacin anhydrous: Link to the compound information in Wikipedia.". https://en.wikipedia.org/wiki/Levofloxac... (accessed September 18, 2017).
  3. PubChem. "LEVOFLOXACIN". https://pubchem.ncbi.nlm.nih.gov/compoun... (accessed September 18, 2017).
  4. FDA Orange Book. "Patent:6806256: The publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act).". https://www.fda.gov/Drugs/InformationOnD... (accessed September 18, 2017).

Reviews

The results of a survey conducted on ndrugs.com for Levofloxacin 0.5.% Nipro are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Levofloxacin 0.5.% Nipro. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


Consumer reported age

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 22 here

 
| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2017 ndrugs.com All Rights Reserved